Nabriva Therapeutics has filed a patent for new dosing strategies for fosfomycin, a drug used to treat bacterial infections. The patent claims a specific dosing regimen for renally impaired patients, with an initial dose of 6 grams followed by a second dose of 4 grams every 8 hours. The aim is to optimize treatment outcomes and patient safety. GlobalData’s report on Nabriva Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Nabriva Therapeutics, Isotropically modified heterocyclic compounds was a key innovation area identified from patents. Nabriva Therapeutics's grant share as of September 2023 was 58%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for a dosing regimen for fosfomycin treatment
A recently filed patent (Publication Number: US20230248750A1) describes a dosing regimen for administering fosfomycin or a pharmaceutically acceptable salt thereof to renally impaired patients in need of treatment. The dosing regimen varies based on the estimated creatinine clearance of the patient.
For renally impaired patients with an estimated creatinine clearance of between 41-50 mL/min, the dosing regimen involves administering a first dose of 6 grams of fosfomycin or a pharmaceutically acceptable salt intravenously, followed by a second dose of 4 grams every 8 hours. The duration of treatment can range from about 3 days to about 20 days.
For patients with an estimated creatinine clearance of between 31-40 mL/min, the dosing regimen includes a first dose of 6 grams of fosfomycin or a pharmaceutically acceptable salt intravenously, followed by a second dose of 3 grams every 8 hours. The duration of treatment is also from about 3 days to about 20 days.
Patients with an estimated creatinine clearance of between 21-30 mL/min are administered a first dose of 6 grams of fosfomycin or a pharmaceutically acceptable salt intravenously, followed by a second dose of 5 grams every 24 hours. The duration of treatment remains the same, ranging from about 3 days to about 20 days.
For patients diagnosed with a cUTI (complicated urinary tract infection) and an estimated creatinine clearance of between 11-20 mL/min, the dosing regimen involves a first dose of 6 grams of fosfomycin or a pharmaceutically acceptable salt intravenously, followed by a second dose of 3 grams every 24 hours. The duration of treatment is also from about 3 days to about 20 days.
Overall, this patent provides specific dosing regimens for administering fosfomycin or its pharmaceutically acceptable salt to renally impaired patients based on their estimated creatinine clearance. The dosing regimens vary in terms of dosage and frequency of administration, with the duration of treatment ranging from about 3 days to about 20 days. These dosing regimens aim to provide effective treatment for patients with different levels of renal impairment.
To know more about GlobalData’s detailed insights on Nabriva Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
